Cargando…
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
IMPORTANCE: The 2017 international PACIFIC trial established a role for immunotherapy after chemoradiation for unresectable stage III non–small cell lung cancer (NSCLC). However, in the US, patients with NSCLC commonly differ from clinical trial populations in terms of age, health, access to care, a...
Autores principales: | Pichert, Matthew D., Canavan, Maureen E., Maduka, Richard C., Li, Andrew X., Ermer, Theresa, Zhan, Peter L., Kaminski, Michael, Udelsman, Brooks V., Blasberg, Justin D., Park, Henry S., Goldberg, Sarah B., Boffa, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353596/ https://www.ncbi.nlm.nih.gov/pubmed/35925606 http://dx.doi.org/10.1001/jamanetworkopen.2022.24478 |
Ejemplares similares
-
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
por: Pichert, Matthew D., et al.
Publicado: (2022) -
Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
por: Ermer, Theresa, et al.
Publicado: (2022) -
Assessment of a collaborative treatment model for trimodal management of esophageal cancer
por: Udelsman, Brooks V., et al.
Publicado: (2023) -
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
por: Zhan, Peter Lee, et al.
Publicado: (2022) -
Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer
por: Zhan, Peter L., et al.
Publicado: (2022)